BioNTech SE BNTX shares are trading higher on Thursday, after the company said it would partner with Pfizer PFE to initiate first clinical trials of the coronavirus vaccine as early as this month.
The company will receive $185 million upfront and is eligible for up to $563 million in milestones.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases.
BioNTech SE shares were trading up 8.39% at $48.72 on Thursday. The stock has a 52-week high of $105 and a 52-week low of $12.52.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.